FDA Gives Emergency Use Nod For Roche's Arthritis Drug Against Severe COVID-19

by Vandana Singh, Benzinga Editor

June 25, 2021 8:19 AM | 1 min read |

The FDA has approved Roche Holding AG's RHHBY arthritis drug Actemra (tocilizumab) for emergency use to treat adults and pediatric patients hospitalized with COVID-19.
It was already allowed to be administered on compassionate grounds.
The drug can be used to treat patients who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation.
The authorization is based on results from four randomized, controlled studies that evaluated Actemra for the treatment of COVID-19 in more than 5,500 hospitalized patients.
Price Action: RHHBY shares are up 1% at $46.6 during the premarket session on the last check Friday.

Posted In: Biotech News Health Care FDA General Arthritis Briefs Covid-19

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.